eCite Digital Repository

Immune checkpoints in targeted-immunotherapy of pancreatic cancer: new hope for clinical development

Citation

Kiaie, SH and Sanaei, MJ and Heshmati, M and Asadzadeh, Z and Azimi, I and Hadidi, S and Jafari, R and Baradaran, B, Immune checkpoints in targeted-immunotherapy of pancreatic cancer: new hope for clinical development, Acta Pharmaceutica Sinica B ISSN 2211-3835 (2020) [Substantial Review]


Preview
PDF
Pending copyright assessment - Request a copy
919Kb
  

DOI: doi:10.1016/j.apsb.2020.12.011

Abstract

Immunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or few effective treatment options thus far. In this process, immunosuppression in the tumor microenvironment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosuppression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest studies to clinical applications of ICP-targeted therapy in PCa.

Item Details

Item Type:Substantial Review
Keywords:targeted-immunotherapy, pancreatic cancer
Research Division:Biomedical and Clinical Sciences
Research Group:Immunology
Research Field:Tumour immunology
Objective Division:Health
Objective Group:Clinical health
Objective Field:Treatment of human diseases and conditions
UTAS Author:Azimi, I (Dr Iman Azimi)
ID Code:143391
Year Published:2020
Deposited By:Pharmacy
Deposited On:2021-03-15
Last Modified:2021-05-04
Downloads:0

Repository Staff Only: item control page